Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC. We’re routinely using next-generation sequencing [NGS] in ...

Two abstracts involving real-world data (RWD) presented at the 2021 American Society of Clinical Oncology Quality Care Symposium tracked the uptake of next-generation sequencing (NGS) and biomarker ...

Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic ...

New Working Group to Evaluate Clinical Utility of NGS-Based Testing to Inform Coverage After many years of steady development in DNA sequencing, the scientific community is reaching an exciting ...

In this presentation, we will discuss the hematopathologist’s perspective on the clinical impact of recent advancements in NGS testing. Learning Objectives: 1. Understand the contribution of genetic ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

WAYNE, Pa. & PARIS--(BUSINESS WIRE)--PathoQuest, a leader in the development and provision of Next Generation Sequencing (NGS) testing services for the biopharmaceutical industry, today announced that ...

Clinical utility of next-generation sequencing (NGS)-based genomic profiling of advanced solid tumors in routine clinical practice. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I ...